Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences By: Taysha Gene Therapies, Inc. via Business Wire November 08, 2021 at 07:00 AM EST Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT 4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference. Conference Details: Event: Stifel 2021 Virtual Healthcare Conference Date: November 15, 2021 Time: 11:20 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Jefferies London Healthcare Conference Date: November 17, 2021 Time: 12:20 pm GMT Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 4th Annual Evercore ISI HealthCONx Virtual Conference Date: November 30, 2021 Time: 4:20 pm ET Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005219/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences By: Taysha Gene Therapies, Inc. via Business Wire November 08, 2021 at 07:00 AM EST Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT 4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference. Conference Details: Event: Stifel 2021 Virtual Healthcare Conference Date: November 15, 2021 Time: 11:20 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Jefferies London Healthcare Conference Date: November 17, 2021 Time: 12:20 pm GMT Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 4th Annual Evercore ISI HealthCONx Virtual Conference Date: November 30, 2021 Time: 4:20 pm ET Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005219/en/Contacts Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com
Stifel 2021 Virtual Healthcare Conference on November 15, 2021 at 11:20 am ET Jefferies London Healthcare Conference November 17, 2021 at 12:20 pm GMT 4th Annual Evercore ISI HealthCONx Virtual Conference on November 30, 2021 at 4:20 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference. Conference Details: Event: Stifel 2021 Virtual Healthcare Conference Date: November 15, 2021 Time: 11:20 am ET Format: Fireside Chat Participants: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: Jefferies London Healthcare Conference Date: November 17, 2021 Time: 12:20 pm GMT Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations Event: 4th Annual Evercore ISI HealthCONx Virtual Conference Date: November 30, 2021 Time: 4:20 pm ET Format: Fireside Chat Participant: RA Session II, President, Founder and Chief Executive Officer Dr. Suyash Prasad, Chief Medical Officer and Head of R&D Kamran Alam, Chief Financial Officer Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005219/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate Communications and Investor Relations Taysha Gene Therapies klee@tayshagtx.com Media Contact: Carolyn Hawley Canale Communications carolyn.hawley@canalecomm.com